Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: an empiric study.
Antimicrobial treatment of acute infection caused by verocytotoxin toxin-producing Escherichia coli (VTEC) is controversial due to risk of inducing haemolytic uraemic syndrome. We review the treatment of 9 persons who experienced serious social problems due to prolonged, asymptomatic carriage of non-O157 VTEC. Eradication of VTEC was successful and without complications.
Jensen
Charlotte
C
Unit of Gastrointestinal Infections, Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark.
Schiellerup
Peter
P
Olsen
Katharina
K
Scheutz
Flemming
F
Petersen
Eskild
E
Gerner-Smidt
Peter
P
Mølbak
Kåre
K
D000328:Adult; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D003718:Denmark / Q000453:epidemiology; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012703:Serotyping; D022603:Shiga Toxins / Q000145:classification*
D000890:Anti-Infective Agents; D022603:Shiga Toxins; D002939:Ciprofloxacin; D000667:Ampicillin